Q1 EPS Estimate for DENTSPLY SIRONA Decreased by Analyst

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) - Research analysts at Barrington Research cut their Q1 2025 earnings per share estimates for DENTSPLY SIRONA in a research report issued to clients and investors on Friday, February 28th. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will earn $0.28 per share for the quarter, down from their prior forecast of $0.38. Barrington Research currently has a "Outperform" rating and a $20.00 target price on the stock. The consensus estimate for DENTSPLY SIRONA's current full-year earnings is $1.84 per share. Barrington Research also issued estimates for DENTSPLY SIRONA's Q4 2025 earnings at $0.55 EPS, FY2025 earnings at $1.86 EPS, Q1 2026 earnings at $0.37 EPS, Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.57 EPS, Q4 2026 earnings at $0.59 EPS, FY2026 earnings at $2.05 EPS and FY2027 earnings at $2.30 EPS.

A number of other research firms have also commented on XRAY. Leerink Partners lowered DENTSPLY SIRONA from an "outperform" rating to a "market perform" rating in a research report on Thursday, November 7th. Jefferies Financial Group lowered DENTSPLY SIRONA from a "buy" rating to a "hold" rating and lowered their price target for the company from $30.00 to $20.00 in a research report on Thursday, January 23rd. UBS Group lowered their price target on DENTSPLY SIRONA from $35.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, December 3rd. Leerink Partnrs lowered DENTSPLY SIRONA from a "strong-buy" rating to a "hold" rating in a research report on Thursday, November 7th. Finally, Wells Fargo & Company lowered their price target on DENTSPLY SIRONA from $20.00 to $19.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Eleven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $23.58.

DENTSPLY SIRONA Stock Up 0.7 %

Shares of NASDAQ:XRAY traded up $0.11 during trading on Monday, reaching $16.26. 2,609,787 shares of the stock were exchanged, compared to its average volume of 2,605,293. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.25 and a quick ratio of 0.84. DENTSPLY SIRONA has a 1-year low of $15.47 and a 1-year high of $34.28. The stock has a fifty day moving average of $18.65 and a two-hundred day moving average of $21.28. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -7.86, a price-to-earnings-growth ratio of 1.80 and a beta of 0.96.

DENTSPLY SIRONA Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 11th. Stockholders of record on Friday, March 28th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 3.94%. The ex-dividend date of this dividend is Friday, March 28th. DENTSPLY SIRONA's dividend payout ratio is presently -14.07%.

Insider Activity

In other news, Director Gregory T. Lucier purchased 15,142 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was bought at an average price of $16.51 per share, for a total transaction of $249,994.42. Following the purchase, the director now owns 81,971 shares of the company's stock, valued at $1,353,341.21. The trade was a 22.66 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.52% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of DENTSPLY SIRONA by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 20,183,260 shares of the medical instruments supplier's stock worth $383,078,000 after acquiring an additional 65,478 shares during the period. First Eagle Investment Management LLC grew its stake in shares of DENTSPLY SIRONA by 2.5% during the 4th quarter. First Eagle Investment Management LLC now owns 14,500,409 shares of the medical instruments supplier's stock worth $275,218,000 after acquiring an additional 348,532 shares during the period. Nuance Investments LLC boosted its stake in DENTSPLY SIRONA by 25.0% in the 4th quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier's stock worth $257,103,000 after purchasing an additional 2,708,097 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in DENTSPLY SIRONA by 18.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier's stock worth $238,186,000 after purchasing an additional 1,975,404 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in DENTSPLY SIRONA by 2.8% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 11,539,418 shares of the medical instruments supplier's stock worth $219,018,000 after purchasing an additional 314,343 shares during the period. Institutional investors own 95.70% of the company's stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.